Plain-English translation of NCT06471257 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a rescue inhaler containing budesonide and albuterol (PT027) works better and is safer than a rescue inhaler with just albuterol (PT007) for adults in China who have symptomatic asthma. About 1,000 people will be randomly assigned to use one of these two medications as needed when asthma symptoms occur or before exercise. The study will last at least 24 weeks and up to 52 weeks, and researchers will track how often asthma flare-ups happen and how safe the treatment is.
People with asthma often need rescue inhalers to quickly relieve symptoms, but researchers want to know if adding a steroid medication (budesonide) to the rescue inhaler might prevent asthma flare-ups better than using a rescue inhaler alone. This trial will help doctors understand whether this medication combination is a more effective option for people whose asthma isn't well controlled.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic for a screening period of 2–4 weeks, then be randomly assigned to use one of the two rescue inhalers as needed whenever asthma symptoms occur or before exercise. You will continue any regular asthma maintenance medications you're already taking. During the treatment period of 6–12 months, you'll have regular clinic visits where the study team will check your lung function, ask about your symptoms, and track how often you need to use your rescue inhaler. After the treatment ends, you'll have one final safety follow-up visit about 2 weeks later.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
China